Profile
John Choi is currently the Vice President of Regulatory Affairs at TFF Pharmaceuticals, Inc. He previously held the same position at Stellular Bio, Inc., Ambys Medicines, Inc., and Abata Therapeutics, Inc. Mr. Choi received his undergraduate and graduate degrees from The Johns Hopkins University.
John Choi active positions
| Companies | Position | Start |
|---|---|---|
| TFF PHARMACEUTICALS, INC. | General Counsel | - |
Former positions of John Choi
| Companies | Position | End |
|---|---|---|
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | General Counsel | - |
Stellular Bio, Inc.
Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to produce independent human platelets from human induced pluripotent stem cells | General Counsel | - |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | General Counsel | - |
Training of John Choi
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 5 |
|---|---|
The Johns Hopkins University
The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stellular Bio, Inc.
Stellular Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Develops technology to produce independent human platelets from human induced pluripotent stem cells | Commercial Services |
TFF Pharmaceuticals, Inc.
TFF Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures inhaled dry powder drugs for the treatment of pulmonary diseases and conditions | Health Technology |
Ambys Medicines, Inc.
Ambys Medicines, Inc. Pharmaceuticals: MajorHealth Technology Develops regenerative medicine therapies for serious liver diseases | Health Technology |
Abata Therapeutics, Inc.
Abata Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treg cell therapies for serious autoimmune and inflammatory diseases | Health Technology |
- Stock Market
- Insiders
- John Choi
















